Wang Y, Bui T, Yang X, Hutvagner G, Deng W
Cancer Metastasis Rev. 2025; 44(1):24.
PMID: 39820726
PMC: 11748474.
DOI: 10.1007/s10555-025-10243-9.
Najumudeen A, Fey S, Millett L, Ford C, Gilroy K, Gunduz N
Nat Commun. 2024; 15(1):100.
PMID: 38168062
PMC: 10762264.
DOI: 10.1038/s41467-023-44342-4.
Ozdemir E, Koester A, Nan X
Genes (Basel). 2022; 13(2).
PMID: 35205266
PMC: 8872464.
DOI: 10.3390/genes13020219.
Yan H, Yu C, Fine S, Youssof A, Yang Y, Yan J
Oncogene. 2021; 40(50):6759-6771.
PMID: 34663879
PMC: 8688281.
DOI: 10.1038/s41388-021-02040-9.
Mysore V, Zhou Z, Ambrogio C, Li L, Kapp J, Lu C
Nat Struct Mol Biol. 2021; 28(10):847-857.
PMID: 34625747
PMC: 8643099.
DOI: 10.1038/s41594-021-00667-6.
BMP4 and PHLDA1 are plausible drug-targetable candidate genes for KRAS G12A-, G12D-, and G12V-driven colorectal cancer.
Ohnami S, Maruyama K, Chen K, Takahashi Y, Hatakeyama K, Ohshima K
Mol Cell Biochem. 2021; 476(9):3469-3482.
PMID: 33982211
PMC: 8342352.
DOI: 10.1007/s11010-021-04172-8.
Pharmacological targeting of RAS: Recent success with direct inhibitors.
OBryan J
Pharmacol Res. 2018; 139:503-511.
PMID: 30366101
PMC: 6360110.
DOI: 10.1016/j.phrs.2018.10.021.
Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens.
Christodoulou E, Yang H, Lademann F, Pilarsky C, Beyer A, Schroeder M
Oncotarget. 2017; 8(21):34283-34297.
PMID: 28415695
PMC: 5470967.
DOI: 10.18632/oncotarget.16079.
K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth.
Dalpa E, Gourvas V, Soulitzis N, Spandidos D
Med Oncol. 2016; 34(1):6.
PMID: 27943100
DOI: 10.1007/s12032-016-0862-5.
Intersectin scaffold proteins and their role in cell signaling and endocytosis.
Herrero-Garcia E, OBryan J
Biochim Biophys Acta Mol Cell Res. 2016; 1864(1):23-30.
PMID: 27746143
PMC: 5148706.
DOI: 10.1016/j.bbamcr.2016.10.005.
Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.
Yu C, Qiu W, Juang C, Mansukhani M, Halmos B, Su G
Cancer Lett. 2016; 384:86-93.
PMID: 27725226
PMC: 5507770.
DOI: 10.1016/j.canlet.2016.10.013.
Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer.
Weyandt J, Lampson B, Tang S, Mastrodomenico M, Cardona D, Counter C
PLoS One. 2015; 10(10):e0140253.
PMID: 26452271
PMC: 4599940.
DOI: 10.1371/journal.pone.0140253.
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target.
Chen M, Peters A, Huang T, Nan X
Mini Rev Med Chem. 2015; 16(5):391-403.
PMID: 26423697
PMC: 5421135.
DOI: 10.2174/1389557515666151001152212.
Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
Grabocka E, Pylayeva-Gupta Y, Jones M, Lubkov V, Yemanaberhan E, Taylor L
Cancer Cell. 2014; 25(2):243-56.
PMID: 24525237
PMC: 4063560.
DOI: 10.1016/j.ccr.2014.01.005.
Wild-type K-ras has a tumour suppressor effect on carcinogen-induced murine colorectal adenoma formation.
Luo F, Poulogiannis G, Ye H, Hamoudi R, Dong G, Zhang W
Int J Exp Pathol. 2013; 95(1):8-15.
PMID: 24354449
PMC: 3919644.
DOI: 10.1111/iep.12064.
Switch of FANCL, a key FA-BRCA component, between tumor suppressor and promoter by alternative splicing.
Yuan C, Xu N, Liao J
Cell Cycle. 2012; 11(18):3356.
PMID: 22918243
PMC: 3466542.
DOI: 10.4161/cc.21852.
Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapies.
de Mello R, Marques D, Medeiros R, Araujo A
World J Clin Oncol. 2011; 2(11):367-76.
PMID: 22087435
PMC: 3215775.
DOI: 10.5306/wjco.v2.i11.367.
c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis.
Wang C, Tai Y, Lisanti M, Liao D
Cancer Biol Ther. 2011; 11(7):615-26.
PMID: 21278493
PMC: 3084967.
DOI: 10.4161/cbt.11.7.14688.
Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology.
Wang C, Lisanti M, Liao D
Cell Cycle. 2011; 10(1):57-67.
PMID: 21200143
PMC: 3048075.
DOI: 10.4161/cc.10.1.14449.
Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation.
Kelley L, Ammer A, Hayes K, Martin K, Machida K, Jia L
J Cell Sci. 2010; 123(Pt 22):3923-32.
PMID: 20980387
PMC: 2972274.
DOI: 10.1242/jcs.075200.